| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13112 R49962 |
Marks - Sertraline (Controls exposed to Bupropion), 2021 | Transient tachypnea of the newborn | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.23 [0.84;1.80] C | 172/1,653 35/406 | 207 | 1,653 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10062 R36573 |
Bracero, 2016 | Tachypnea | days before delivery | retrospective cohort | unexposed, sick | Adjustment: No Monotherapy: no or not specified | 1.63 [0.08;34.23] C | 0/6 4/85 | 4 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5430 R21352 |
Norby, 2016 | Transient tachypnea/other respiratory disease | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: no or not specified | 1.70 [1.60;1.90] | 819/17,736 15,860/718,533 | 16,679 | 17,736 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5423 R19475 |
Levinson-Castiel, 2006 | Tachypnea | 3rd trimester | retrospective cohort | unexposed, disease free | Adjustment: No Matched Monotherapy: no or not specified | 31.32 [1.81;542.66] C | 12/60 0/60 | 12 | 60 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.59 [1.06;2.37] | 16,902 | 19,455 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls exposed to Bupropion;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded